CAI vs. TLX

Last updated Jun 24, 2026

CAI (Caris Life Sciences, Inc) and TLX (Telix Pharmaceuticals Ltd) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, CAI returned -32.15% vs -37.71% for TLX. At a 0.12 correlation, their price movements are largely independent.

Performance

CAI vs. TLX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CAI achieves a -34.77% return, which is significantly lower than TLX's 36.32% return.

CAI

• 1D: 1.68%
• 1M: 13.18%
• YTD: -34.77%
• 6M: -37.14%
• 1Y: -32.15%
• 3Y*: —
• 5Y*: —
• 10Y*: —

TLX

• 1D: 2.10%
• 1M: 7.81%
• YTD: 36.32%
• 6M: 26.21%
• 1Y: -37.71%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CAI vs. TLX - Yearly Performance Comparison

	2026 (YTD)	2025
CAI Caris Life Sciences, Inc	-34.77%	-0.07%
TLX Telix Pharmaceuticals Ltd	36.32%	-55.41%

Correlation

The correlation between CAI and TLX is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (All Time) Calculated using the full available price history since Jun 18, 2025	0.12

Fundamentals

Market Cap CAI : $4.97B TLX : $3.46B
EPS CAI : $0.05 TLX : A$0.12
PE Ratio CAI : 327.30 TLX : 127.38
PEG Ratio CAI : 1.25 TLX : 0.16
PS Ratio CAI : 12.26 TLX : 2.50
PB Ratio CAI : 8.38 TLX : 8.04
Total Revenue (TTM) CAI : $907.29M TLX : A$2.00B
Gross Profit (TTM) CAI : $482.11M TLX : A$1.13B
EBITDA (TTM) CAI : $92.24M TLX : A$153.71M

Return for Risk

CAI vs. TLX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CAI

CAI Risk / Return Rank: 23
CAI Sharpe Ratio Rank: 20
CAI Sortino Ratio Rank: 23
CAI Omega Ratio Rank: 23
CAI Calmar Ratio Rank: 25
CAI Martin Ratio Rank: 26

TLX

TLX Risk / Return Rank: 19
TLX Sharpe Ratio Rank: 14
TLX Sortino Ratio Rank: 16
TLX Omega Ratio Rank: 17
TLX Calmar Ratio Rank: 20
TLX Martin Ratio Rank: 25

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CAI vs. TLX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CAI	TLX	Difference
Sharpe ratio: Return per unit of total volatility	-0.51	-0.65	+0.14
Sortino ratio: Return per unit of downside risk	-0.40	-0.76	+0.36
Omega ratio: Gain probability vs. loss probability	0.95	0.91	+0.04
Calmar ratio: Return relative to maximum drawdown	-0.51	-0.61	+0.10
Martin ratio: Return relative to average drawdown	-0.85	-0.88	+0.03

CAI vs. TLX - Sharpe Ratio Comparison

The current CAI Sharpe Ratio is -0.51, which is comparable to the TLX Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of CAI and TLX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CAI vs. TLX - Drawdown Comparison

The maximum CAI drawdown since its inception was -62.98%, smaller than the maximum TLX drawdown of -69.37%. Use the drawdown chart below to compare losses from any high point for CAI and TLX.

Drawdown Indicators

	CAI	TLX	Difference
Max Drawdown Largest peak-to-trough decline	-62.98%	-69.37%	+6.39%
Max Drawdown (1Y) Largest decline over 1 year	-62.98%	-62.12%	-0.86%
Current Drawdown Current decline from peak	-55.22%	-51.22%	-4.00%
Average Drawdown Average peak-to-trough decline	-32.18%	-37.10%	+4.92%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.66%	42.86%	-5.20%

Volatility

CAI vs. TLX - Volatility Comparison

Caris Life Sciences, Inc (CAI) has a higher volatility of 19.65% compared to Telix Pharmaceuticals Ltd (TLX) at 14.76%. This indicates that CAI's price experiences larger fluctuations and is considered to be riskier than TLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CAI	TLX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.65%	14.76%	+4.89%
Volatility (6M) Calculated over the trailing 6-month period	48.65%	40.12%	+8.53%
Volatility (1Y) Calculated over the trailing 1-year period	62.85%	58.24%	+4.61%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.77%	56.86%	+5.91%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.77%	56.86%	+5.91%

Dividends

CAI vs. TLX - Dividend Comparison

Neither CAI nor TLX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

CAI vs. TLX - Profitability Comparison

The chart below illustrates the profitability comparison between Caris Life Sciences, Inc and Telix Pharmaceuticals Ltd over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CAI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a gross profit of 0.00 and revenue of 216.17M. Therefore, the gross margin over that period was 0.0%.

TLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a gross profit of 327.42M and revenue of 620.44M. Therefore, the gross margin over that period was 52.8%.

CAI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported an operating income of 5.28M and revenue of 216.17M, resulting in an operating margin of 2.4%.

TLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported an operating income of 9.82M and revenue of 620.44M, resulting in an operating margin of 1.6%.

CAI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a net income of -510.00K and revenue of 216.17M, resulting in a net margin of -0.2%.

TLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a net income of -7.25M and revenue of 620.44M, resulting in a net margin of -1.2%.

Frequently Asked Questions

Can I hold both CAI and TLX in my portfolio?

CAI and TLX have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CAI or TLX?

CAI has higher volatility (19.65%) compared to TLX (14.76%). In terms of maximum drawdown, CAI dropped -62.98% vs TLX's -69.37%.

Which has better risk-adjusted returns?

CAI currently has the higher Sharpe Ratio (-0.51 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.